Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee

NCT ID: NCT00722852

Last Updated: 2009-10-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

555 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to provide replicated evidence of safety and efficacy of 100 mg ketoprofen in Diractin®.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will investigate safety and efficacy of Diractin® at relieving signs and symptoms of knee OA, including the primary endpoint of patient assessment of pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis of the Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

ketoprofen in Diractin®

Intervention Type DRUG

100 mg (b.i.d.)

2

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

100 mg (b.i.d.)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ketoprofen in Diractin®

100 mg (b.i.d.)

Intervention Type DRUG

Placebo

100 mg (b.i.d.)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent signed and dated
* Age \> 45 years
* Class I-III OA of the knee and subject meets American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis of the knee

Exclusion Criteria

* Skin lesions or dermatological diseases in the treatment area
* Directly or indirectly involved in the conduct and administration of this study
* Received any investigational medicinal product within 30 days prior to Screening Visit or participation in any previous clinical study with Diractin®
* Pregnancy or lactation
* Residents of psychiatric wards, prisons or other state institutions
* Malignancy within the past 2 years
* Depressive disorders requiring treatment with tricyclics, treatment with other antidepressants must be stable for 3 months prior to screening and throughout the study
* Epilepsy
* Schizophrenia
* Neuropathic pain and any other pain condition requiring chronic use of pain medication
* Known hypersensitivity or allergy (including photoallergy) to NSAID´s including ketoprofen and to ingredients of the IMP
* Preexisting asthma or bronchospasm after taking aspirin or other NSAIDs
* Unable to discontinue analgesic therapy including opioids, NSAID´s, tramadol, muscle relaxants, gabapentin, pregabalin, duloxetine, venlafaxine, capsaicine or other drugs approved or used for the treatment of pain for the duration of the study
Minimum Eligible Age

46 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IDEA AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

IDEA AG

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

IDEA AG

Role: STUDY_DIRECTOR

IDEA AG

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hope Research Institute

Phoenix, Arizona, United States

Site Status

Premiere Pharmaceutical Research

Tempe, Arizona, United States

Site Status

Genova Clinical Research

Tucson, Arizona, United States

Site Status

Family Practice Lynn Institute of the Ozarks

Little Rock, Arkansas, United States

Site Status

Orange County Clinical Trails, Inc.

Anaheim, California, United States

Site Status

Encompass Clinical Research

Spring Valley, California, United States

Site Status

Tampa Bay Medical Research Inc.

Clearwater, Florida, United States

Site Status

University Clinical Research DeLand, LCC

DeLand, Florida, United States

Site Status

Eastern Research

Hialeah, Florida, United States

Site Status

DSI

Jupiter, Florida, United States

Site Status

FPA Clinical Research

Kissimmee, Florida, United States

Site Status

Suncoast Clinical Research Family Practice

New Port Richey, Florida, United States

Site Status

Renstar Medical Research

Ocala, Florida, United States

Site Status

University Clinical Research, Inc.

Pembroke Pines, Florida, United States

Site Status

Miami Research Associates

South Miami, Florida, United States

Site Status

Drug Studies America

Marietta, Georgia, United States

Site Status

Non-Surgical Orthopaedic & Spine Center, P.C.

Marietta, Georgia, United States

Site Status

Clinical Research Atlanta

Stockbridge, Georgia, United States

Site Status

Advance Clinical Research Insititute

Boise, Idaho, United States

Site Status

MediSphere Medical Research Center, LLC

Evansville, Indiana, United States

Site Status

Integrated Clinical Trail Services, Inc.

West Des Moines, Iowa, United States

Site Status

Lousianna Research Associates Inc. (LRC, Inc)

New Orleans, Louisiana, United States

Site Status

Future Care Studies

Springfield, Massachusetts, United States

Site Status

Westside Family Medical Center, P.C.

Kalamazoo, Michigan, United States

Site Status

Omaha Research, P.C.

Omaha, Nebraska, United States

Site Status

Rochester Clinical Research

Rochester, New York, United States

Site Status

Wake Research Associates, LLC

Raleigh, North Carolina, United States

Site Status

The Center of Clinical Research LLC

Winston-Salem, North Carolina, United States

Site Status

Rapid Medical Research, Inc.

Cleveland, Ohio, United States

Site Status

Pharcotherapy Research Associate, Inc.

Zanesville, Ohio, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Founders Research Group Research

Philadelphia, Pennsylvania, United States

Site Status

Omega Medical Research

Warwick, Rhode Island, United States

Site Status

Coastal Carolina Research Center

Goose Creek, South Carolina, United States

Site Status

Sarah Cannon Research Institute

Jackson, Tennessee, United States

Site Status

Quality Research Inc.

San Antonio, Texas, United States

Site Status

Progressive Clinical Research

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Rother M, Conaghan PG. A randomized, double-blind, phase III trial in moderate osteoarthritis knee pain comparing topical ketoprofen gel with ketoprofen-free gel. J Rheumatol. 2013 Oct;40(10):1742-8. doi: 10.3899/jrheum.130192. Epub 2013 Sep 1.

Reference Type DERIVED
PMID: 23996292 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CL-033-III-06

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.